RxSight CMO swaps options for $6.375 strike

Chief Medical Officer Ronald M. Kurtz, MD exchanged multiple RxSight stock options for new grants with a lower exercise price and revised vesting terms.

Rhea-AI Filing Summary

RxSight, Inc. reported that Chief Medical Officer Ronald M. Kurtz, MD adjusted his equity awards on September 5, 2026 in connection with an option exchange program. He returned four outstanding stock option grants to the company and received four replacement options with a lower exercise price of $6.375 per share, each with specified vesting schedules tied to continued service.

Insider Trade Summary

8 transactions reported

Mixed 8 txns

Insider Kurtz Ronald M MD

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Disposition	Stock option (right to buy) F1	338,819	--	--
Disposition	Stock Option (right to buy) F3, F2	200,000	--	--
Disposition	Stock Option (right to buy) F5, F4	149,000	--	--
Disposition	Stock Option (right to buy) F1, F6	215,000	--	--
Grant/Award	Stock Option (right to buy) F1, F7	254,751	--	--
Grant/Award	Stock Option (right to buy) F3, F8	173,913	--	--
Grant/Award	Stock Option (right to buy) F5, F9	96,129	--	--
Grant/Award	Stock Option (right to buy) F1, F10	161,654	--	--

Holdings After Transaction: Stock option (right to buy) — 686,447 contracts (Direct)

Footnotes (10)

1. F1. On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.33:1 basis with a post-exchange exercise price of $6.375 per share.
2. F2. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 9, 2023.
3. F3. On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.15:1 basis with a post-exchange exercise price of $6.375 per share.
4. F4. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 4, 2024.
5. F5. On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.55:1 basis with a post-exchange exercise price of $6.375 per share.
6. F6. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean February 27, 2025.
7. F7. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, 25% of the shares subject to the option will vest on February 28, 2027 and the remaining 75% of the shares subject to the option will vest on August 31, 2027.
8. F8. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, 25% of the 148,549 shares subject to the option will vest on February 28, 2027 and the remaining 75% of the 148,549 shares subject to the option will vest on August 31, 2027. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one twenty-fourth (1/24th) of the 25,364 shares subject to the option will vest on February 28, 2027 and in equal monthly installments thereafter.
9. F9. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, 25% of the 60,080 shares subject to the option will vest on February 28, 2027 and the remaining 75% of the 60,080 shares subject to the option will vest on August 31, 2027. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one twenty-fourth (1/24th) of the 36,049 shares subject to the option will vest on February 28, 2027 and in equal monthly installments thereafter.
10. F10. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, 25% of the 60,620 shares subject to the option will vest on February 28, 2027 and the remaining 75% of the 60,620 shares subject to the option will vest on August 31, 2027. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one twenty-fourth (1/24th) of the 101,034 shares subject to the option will vest on February 28, 2027 and in equal monthly installments thereafter.

Key Figures

Options returned at $16.00: 338,819 options Options returned at $14.95: 200,000 options Options returned at $56.07: 149,000 options +5 more

8 metrics

Options returned at $16.00 338,819 options Options to buy RxSight common stock with a $16.00 exercise price returned to the issuer on September 5, 2026

Options returned at $14.95 200,000 options Options with a $14.95 exercise price returned to the issuer on September 5, 2026

Options returned at $56.07 149,000 options Options with a $56.07 exercise price returned to the issuer on September 5, 2026

Options returned at $28.21 215,000 options Options with a $28.21 exercise price returned to the issuer on September 5, 2026

New options at $6.375 254,751 options New stock option grant with a $6.375 exercise price expiring September 4, 2033

Additional new options at $6.375 173,913 options New stock option grant with a $6.375 exercise price expiring September 4, 2033

Cliff vesting date February 28, 2027 25% of certain new option grants vest on February 28, 2027, subject to continued service

Final vesting date August 31, 2027 Remaining 75% of certain new option grants vest on August 31, 2027, subject to continued service

Key Terms

option exchange program, Vesting Commencement Date, Service Provider, 2021 Equity Incentive Plan

4 terms

option exchange program financial

"On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged"

Vesting Commencement Date financial

""Vesting Commencement Date" shall mean March 9, 2023."

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

Service Provider financial

"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan)"

2021 Equity Incentive Plan financial

"as defined in the Issuer's 2021 Equity Incentive Plan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider equity changes were reported for RXST on September 5, 2026?

On September 5, 2026, RxSight’s Chief Medical Officer Ronald M. Kurtz, MD returned four outstanding stock option grants and received four new stock option grants as part of an option exchange program, all with a $6.375 exercise price and updated vesting schedules.

Did the RXST filing show option grants or cancellations for the Chief Medical Officer?

Both. The Chief Medical Officer surrendered four existing stock option awards covering 338,819, 200,000, 149,000 and 215,000 shares and received four new stock option grants covering 254,751, 173,913, 96,129 and 161,654 shares, all at an exercise price of $6.375.

What were the exercise prices of the RXST options affected in this Form 4?

The options returned had exercise prices of $16.00, $14.95, $56.07 and $28.21 per share. All replacement options granted on September 5, 2026 carry a new exercise price of $6.375 per share under the option exchange program.

How do the new RXST options for the Chief Medical Officer vest?

For certain exchanged options, one forty-eighth of the shares vests monthly from Vesting Commencement Dates of March 9, 2023, March 4, 2024, or February 27, 2025. Other new grants vest 25% on February 28, 2027 and 75% on August 31, 2027, with portions vesting monthly thereafter.

Were the RXST insider transactions under a Rule 10b5-1 trading plan?

No. The filing indicates that these option exchanges and grants for the Chief Medical Officer were not reported as being made under a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 08:54 PM EDT Accepted by SEC EDGAR 09/09/2026 - 08:53 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kurtz Ronald M MD

(Last) (First) (Middle)

C/O RXSIGHT, INC.

100 COLUMBIA

(Street)

ALISO VIEJO CALIFORNIA 92656

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RxSight, Inc. [ RXST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$16	09/05/2026		D			338,819	07/30/2025	07/30/2031	Common Stock	338,819	(1)	0	D
Stock Option (right to buy)	$14.95	09/05/2026		D			200,000	(2)	03/08/2033	Common Stock	200,000	(3)	0	D
Stock Option (right to buy)	$56.07	09/05/2026		D			149,000	(4)	03/03/2034	Common Stock	149,000	(5)	0	D
Stock Option (right to buy)	$28.21	09/05/2026		D			215,000	(6)	02/26/2035	Common Stock	215,000	(1)	0	D
Stock Option (right to buy)	$6.375	09/05/2026		A		254,751		(7)	09/04/2033	Common Stock	254,751	(1)	254,751	D
Stock Option (right to buy)	$6.375	09/05/2026		A		173,913		(8)	09/04/2033	Common Stock	173,913	(3)	173,913	D
Stock Option (right to buy)	$6.375	09/05/2026		A		96,129		(9)	09/04/2033	Common Stock	96,129	(5)	96,129	D
Stock Option (right to buy)	$6.375	09/05/2026		A		161,654		(10)	09/04/2033	Common Stock	161,654	(1)	161,654	D

Explanation of Responses:

1. On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.33:1 basis with a post-exchange exercise price of $6.375 per share.

2. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 9, 2023.

3. On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.15:1 basis with a post-exchange exercise price of $6.375 per share.

4. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 4, 2024.

5. On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.55:1 basis with a post-exchange exercise price of $6.375 per share.

6. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean February 27, 2025.

7. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, 25% of the shares subject to the option will vest on February 28, 2027 and the remaining 75% of the shares subject to the option will vest on August 31, 2027.

8. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, 25% of the 148,549 shares subject to the option will vest on February 28, 2027 and the remaining 75% of the 148,549 shares subject to the option will vest on August 31, 2027. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one twenty-fourth (1/24th) of the 25,364 shares subject to the option will vest on February 28, 2027 and in equal monthly installments thereafter.

9. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, 25% of the 60,080 shares subject to the option will vest on February 28, 2027 and the remaining 75% of the 60,080 shares subject to the option will vest on August 31, 2027. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one twenty-fourth (1/24th) of the 36,049 shares subject to the option will vest on February 28, 2027 and in equal monthly installments thereafter.

10. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, 25% of the 60,620 shares subject to the option will vest on February 28, 2027 and the remaining 75% of the 60,620 shares subject to the option will vest on August 31, 2027. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one twenty-fourth (1/24th) of the 101,034 shares subject to the option will vest on February 28, 2027 and in equal monthly installments thereafter.

	/s/ Jim Schindler, as Attorney-in-Fact	09/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)